Relmacabtagene Autoleucel in Hematologic Malignancies
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorShanghai Ming Ju Biotechnology Co., Ltd.
About this trial
To evaluate the efficacy and safety of Relmacabtagene Autoleucel in the treatment of adult patients with hematologic malignancies in real-world
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Signed informed consent
Patients who have been treated with Relma-cel, including those who have received off-label products;
If previously enrolled in another clinical study, they must have completed follow-up in the previous study, or have withdrawn or lost follow-up in the previous study.
Disqualifiers
None
Trial population
Hematologic Malignancies
Trial design
Design model
Case-only
Time perspective
Retrospective
Treatments tested in this trial
Relmacabtagene Autoleucel
Biological/VaccineA single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells
Treatment groups
150 Participants
are divided into 1 treatment groupGroup A: Relmacabtagene Autoleucel1 intervention
Trial outcomes
Primary outcomes
1
ORR
Percentage of participants with CR \[CMR;CRR\] or PR \[partial metabolic response (PMR);
Time frame
15 yearsSecondary outcomes
1
CRR
Complete response rate
Time frame
15 years2
Duration of response (DOR)
Time from first response(PR or CR) to disease progression or death from any cause.
Time frame
15 years3
Progression-Free Survival (PFS)
PFS is defined as the time from the Relmacabtagene Autoleucel infusion date to the date of disease progression per Lugano classification or death from any cause.
Time frame
15 years4
Overall Survival (OS)
OS is defined as the time from Relmacabtagene Autoleucel infusion to the date of death from any cause.
Time frame
15 yearsSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov
This trial is not recruiting at the moment. You can still explore other options: